Japan Approves Updated COVGOZE® COVID-19 Vaccine for Omicron LP.8.1 Strain

Shionogi & Co., Ltd. announced that its recombinant protein COVID-19 vaccine, COVGOZE® for Intramuscular Injection, has received partial change approval in Japan. The approval updates the vaccine's antigen strain to Omicron LP.8.1, which is the recommended strain for the 2026/2027 vaccination season. Shionogi is preparing to supply the updated vaccine in fiscal year 2026.

Context

Shionogi & Co., Ltd. has been involved in the development of COVID-19 vaccines since the pandemic began. The original COVGOZE® vaccine was designed to combat earlier strains of the virus. As new variants emerge, vaccine updates are necessary to maintain their effectiveness in protecting the population.

Why it matters

The approval of the updated COVGOZE® vaccine is significant as it addresses the evolving nature of the COVID-19 virus, particularly the Omicron LP.8.1 strain. This development is crucial for public health strategies aimed at controlling the spread of COVID-19. It reflects ongoing efforts to ensure vaccines remain effective against emerging variants.

Implications

The updated vaccine could enhance immunity among the population, potentially reducing hospitalizations and severe cases of COVID-19. This may also influence vaccination rates and public confidence in vaccine efficacy. Vulnerable groups, such as the elderly and those with pre-existing conditions, may particularly benefit from this advancement.

What to watch

Shionogi is expected to start supplying the updated vaccine in fiscal year 2026, which will be a key period for vaccination efforts. Monitoring the rollout and public response to the updated vaccine will be important. Additionally, health authorities may provide guidance on vaccination strategies as the new strain becomes prevalent.